Funding for this research was provided by:
National Cancer Institute (5P30CA045508-30)
Division of Cancer Epidemiology and Genetics, National Cancer Institute (5P30CA045508-30)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R01AR076242-01)
U.S. Department of Defense (W81XWH-18-1-0674)
National Institute of Allergy and Infectious Diseases (U54 AI 082973)
Received: 1 June 2020
Accepted: 7 September 2020
First Online: 29 September 2020
Ethics approval and consent to participate
: The Northwell Health institutional review board that focuses on COVID-19 research approved this case series as minimal-risk research using de-identified data from routine clinical practice. Informed consent to participate in the study was obtained from the participants or their health care proxies. The study has been registered as “Dornase Alfa Administered to Patients With COVID-19 (DACOVID)” at ExternalRef removed with ExternalRef removed Identifier: NCT04387786.
: Not applicable.
: Mikala Egeblad is receiving lonodelestat from Santhera for preclinical studies, but has no financial relationship with Santhera. The other authors declare that they have no competing interests.